Dashboard

Enzo Biochem, Inc. (ENZ)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

S

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

CEO

Elazar Rabbani

Employees

500

Industry

-

Sector

-

Headquarters

New York

Exchange

New York Stock Exchange

Summary Stats

Market Cap

121M

Revenue

98.8M

Net Income

-26.6M

EPS

-$0.55

Price-to-Earnings

-4.45

Price-to-Book

2.68

Debt-to-Equity

0.89

News

Analyst Ratings

Price targets projected by 1 analyst

High

$5.00

Average

$5.50

Low

$5.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2023

Last Earnings

Not Available

Actual

-$0.18 -

Consensus

-

Report Date

Year Ago

-0.04

Year Ago Change %

Down 350%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites